SR9009

SR9009 (Stenabolic) is a synthetic Rev-Erbα/β agonist developed by the Scripps Research Institute. Despite being commonly grouped with SARMs, it has no androgenic mechanism — Rev-Erb is a circadian clock nuclear receptor that regulates metabolic gene expression. Animal data shows dramatic improvements in endurance (50% increase in running capacity), fat mass reduction (60% reduction in diet-induced obesity), and glucose metabolism. The primary clinical limitation is bioavailability — oral bioavailability is extremely poor (~2%), and injectable forms are used in research contexts. SR9011 has better bioavailability. No human RCTs exist. The circadian and metabolic effects are genuinely interesting.